Pfizer Facing Whistleblower Lawsuit Over China FCPA Concerns
Claims 'Unfounded,' Firm Says
Pfizer is facing a US lawsuit alleging wrongful termination and retaliation against a whistleblower after the company’s former director of Global Compliance Analytics discovered what he viewed to be potential violations in China of the US Foreign Corrupt Practices Act.
You may also be interested in...
US Secretary of Commerce Gina Raimondo has made the first official visit to China by a US commerce official in three years, paving the way to possible improvements in bilateral relations. Despite ongoing geopolitical tensions as a major concern for US firms in China, some are returning to growth in the country.
Although the spread of HIV/AIDS appears to be largely under control in China, increasing infections among the elderly are causing concern due to a range of risk factors, while domestic firms move to expand their drug offerings.
Following in the steps of Merck & Co. and GSK, Pfizer is turning to a Chinese partner to more broadly market one of its top vaccines in the country - but the US firm is going one step further.